The first ECVAM workshop, held, like many of its successors, at the Hotel Lido, Angera, Italy, took place on 19-23 October 1993. 1 It dealt with The Practical Applicability of Hepatocyte Cultures in Routine Testing. This topic was chosen because of the major role of the liver in the metabolism and clearance of drugs and other xenobiotics, and also because of the importance of the liver as a target for toxic effects. The outcome was rather disappointing, since, although hepatocyte in vitro systems were already in widespread use at the research level, there was little sign of agreement on detailed procedures and protocols, or of the kinds of independent assessment needed before such systems could be used to satisfy regulatory requirements. Indeed, companies appeared to be reluctant to share their experience with others, presumably because they used it to gain advantage during product development. There was also the problem that primary hepatocyte cultures and hepatocyte cell lines did not retain many of their essential in vivo properties and functions.
That situation remained more or less unchanged for many years, but some dramatic developments have taken place recently, so the future now looks very promising. This has happened for two main reasons.
First, the pharmaceutical industry is in a state of crisis, partly because many drugs have had to be withdrawn late on during development, during clinical trials, and even after they have been accepted for use at the population level, sometimes because of lack of efficacy, and sometimes because of unexpected toxicity. 2 Drug-induced liver injury (DILI) is one of the most common reasons for such withdrawals, 3 and it has emerged that human toxicity is rarely predictable from the pharmacological actions of drugs, and that the concordance between animal toxicity is so poor that animal studies cannot contribute effectively to the decision-making process. 4 The failure to detect DILI at a sufficiently early stage results in both a huge financial cost for the pharmaceutical industry and a real human cost for the patient -75% of the individuals who suffer idiosyncratic liver injury either die or require a transplant. The need for urgent action on DILI has been recognised by the pharmaceutical industry and by national and international government agencies, including the US Food and Drug Administration (FDA) and the European Innovative Medicines Initiative (IMI).
Secondly, a number of major technological developments have opened up possibilities for avoiding the insoluble problems of species differences and animal to human extrapolation, which inevitably limit the value of animal studies. These directly human-based approaches also offer the exciting prospect of dynamic two-way interactions between what takes place in the laboratory and in the clinic. The new methodology will have to be used intelligently, in integrated strategies which take into account the stage of development and application of a new product. At one extreme of a spectrum of methods will be inexpensive, highthroughput systems applicable to large numbers of chemicals at the drug discovery stage, while at the other extreme will be more-sophisticated and expensive systems appropriate for use at much later stages of product development, and even with individual patients. FRAME-associated scientists are involved in these developments, for example, by editing a book on New Technologies for Toxicity Testing, due to be published in July 2011, 5 and by writing chapters for Pharmaceutical Biotechnology -A Compre hensive Handbook 6 and Implant Dentistry Research Guide: Basic, Translational and Experimental Clinical Research. 7 The FRAME Alternatives Laboratory (FAL), in the University of Nottingham's School of Biomedical Sciences, is currently actively involved in the development of DILI testing methods based on the use of patient-derived hepatocytes. ATLA is also playing its part, with two relevant supplements to volumes 37 and 38 (2009 and 2010), and three issues (numbers 4, 5 and 6) in the special anniversary volume, volume 37 (2009). A report on the EU Vitrocellomics project, published in this issue, is of particular importance, 3 as is Kelly BéruBé's article on inhalation toxicology. 8 It must be emphasised that drugs are powerful chemicals which are deliberately applied to the human body and which inevitably are likely to have adverse side-effects. In the evaluation of toxic hazard and the prediction of risk to humans, attention must be focused on the following: a) the evidence that a given drug can cause adverse effect(s) at doses close to the therapeutic dose; b) the frequency of incidence of those effects in a given pop-
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Modern Alternative Approaches to the Problem of Druginduced Liver Injury ulation; c) the degrees of severity of the effects; d) variations in susceptibility to and in the expression of the effects within the population and between populations; and e) the epigenetic factors which can modulate them.
The following brief discussion is intended to provide a flavour of some of the new in vitro technologies and their implications. It does not include developments in relation to in silico technology, high content screening, the omics approaches, physiologically-based pharmacokinetic (PBPK) models, virtual tissue models, virtual patient populations, biomarkers and clinical imaging, which are also of great significance, especially when used in combination with, and with the benefit of, bioinformatics and systems biology approaches. 6 1. Cell fractions: Short-term studies can be conducted with cell fractions and isolated cell components, such as nuclei, membranes, mitochondria and receptors. This can be the basis for high-throughput screening to answer relatively specific and narrow questions. Several drugs have been withdrawn from the market because of mitochondrial toxicity, including nefazodone, an anti-depressant which caused hepatotoxicity. It has been suggested that tests on isolated mitochondria could provide a highthroughput screening tool. It is also possible to use mitochondria to provide information on mechanisms of toxicity, e.g. effects on oxidative phosphorylation and calcium homeostasis, which would have wide implications.
Cell lines:
The cytochrome P-450 (CYP) enzymes are particularly important in the metabolism of drugs and other xenobiotics. It has been possible to produce genetically-engineered cell lines, such as V79 cells, which themselves have little CYP activity, transfected with the main CYP genes from humans. A recently-isolated human hepatoma cell line, HepaRG, expresses many CYPs, and could be a much better model for human drug metabolism studies than many of the pre-existing cell lines, such as HepG2. 9 3. Stem cells: A great deal of effort is being invested in developing stem cell therapeutics, with the hope of replacing diseased or damaged tissues, or even whole organs, in patients. The production of hepatocytes from human embryonic stem cells (hESCs) is an important aspect of the Vitrocellomics project, 3 but the development of procedures for producing pluripotent stem cells from adult somatic cells, i.e. what are known as induced pluripotent stem cells (iPSCs), avoids the ethical issues related to obtaining hESCs. In the future, it may be possible to use iPSCs from an individual patient to provide replacement tissues for that same patient. In relation to drug discovery and development, the use of iPSCs opens up the possibility of producing normal and damaged differentiated cells of various types from individual humans, both before and after drug treatment, in order to conduct detailed studies on the desired and/or adverse effects of the drug, as a means of studying genetic predisposition, dose-effect relationships, and the effects of epigenetic variables, such as treatment with other drugs, life-style and occupational factors, and infections. Functional human hepatocytes have been produced from iPSCs, which could be of great benefit to research on the problem of DILI. 10 4. Tissue engineering: Short-term studies can be conducted with precision-cut slices of organs such as the liver, as a way of investigating DILI in preparations where the organ architecture and cell and tissue relationships are retained. The aim of tissue engineering is to use appropriate strategies to recreate in vitro, the biochemical, mechanical and three-dimensional (3-D) structural conditions under which cells and tissues function in vivo. This involves various approaches, including the following: producing natural extracellular matrix models or synthetic mimics; providing appropriate gradients and cascades of specific growth factors; developing appropriate biomechanical environments; recognising the importance of cell-cell signalling; establishing co-cultures of different cell types; and replicating tissue architecture and medium flow patterns. The materials used in the devices (polymers, textiles, glass, ceramics) are also the subject of further efforts, in order to permit downscalability, processability and detectability, along with the use of membranes for local transport and cell adherence, and microcapillary systems and microfluidics, along with nanotechnology, for the handling of materials on the molecular scale. These kinds of developments are also vital to the provision of the conditions suitable for the maintenance of various tissues in in vitro bioreactors.
Bioreactors:
Bioreactors are devices designed to maintain cells or tissues under conditions where basic substrates (e.g. oxygen, glucose, amino acids) are supplied to, and waste products (e.g. carbon dioxide, ammonia, urea, lactate) are removed from, for example, liver cells maintained at high density in large 3-D constructs involving networks of hollow microfibre membranes which provide the equivalent of a vascular network. 11 The human artificial lymph node (ALN) is a dynamic bioreactor, which provides an interface between a stationary network of antigenproducing cells and a population of suspended, highly migratory, lymphocytes, which are embed-ded in an appropriate environment with stromal cells and an extracellular matrix. 11 The ALN imitates the events that occur in the lymph node, when the flow of lymphatic fluid brings materials which may be antigenic and will induce a response.
Liver bioreactors were originally developed to provide acute liver failure patients with an external artificial liver, to allow time for the selfregeneration of their own livers. Less-complex systems are now being developed, to provide higher throughput opportunities for studies on the biotransformation and elimination of xenobiotics. The report on the Vitrocellomics project described the use of a four-compartment bioreactor, based on a 3-D capillary network, to provide for the dynamic perfusion culture of the hepatocytes. 3 It is even possible to measure respiration in the individual wells of multi-well plates via O 2 sensors immobilised in each of the wells. The work is now being extended to incorporate other sensors, as well as metabolic flux analysis, to permit the early detection of potential toxicity.
Multi-organ systems:
Various multi-organ culture systems are in the course of development, including two described in ATLA, the Hurel TM system 12 and the Integrated Discrete Multiple Organ Culture (IdMOC ® ) system. 13 Hurel involves a microfluidic circuit which links separate compartments containing cells representative of the equivalent tissues or organs in vivo. A culture medium circulates as a 'blood surrogate', and the four compartments of a typical model contain equivalents of 'liver', 'lung', 'fat' and 'other tissues', and the physical features of the model reflect parametric values derived from PBPK models. Hurel permits pro-drug activation and metabolism, and it is possible, for example, to have an anti-cancer pro-drug metabolised in a 'liver' compartment and its effects evaluated on cancer cells in another compartment, in a representation of a tumour-bearing human. As in Hurel, the different organ systems represented in IdMOC, e.g. hepatocytes, kidney proximal cells, pulmonary epithelial cells, and vascular endothelial cells, are maintained independently and connected by microfluidic circulation. The system can be used to study organ-specific cytotoxicity, and also to create an in vitro model of a tumour-bearing man. It also permits the use of precision-cut slices from multiple organs, and enables investigation of the interactions between different cells from the same organ or in vivo system (e.g. small airway epithelial cells, bronchial epithelial cells and pulmonary microvascular endothelial cells).
Another system, the multi-well plate scale Quasi-vivo ® system, 14 is based on a Multi Compartmental Bioreactor (MCB), and cell ratios and medium passage times are scaled to provide more-meaningful physiological relationships, avoiding some of the problems encountered when microfluidics, microfabrication and miniaturisation are pushed too far. Various cell types have now been incorporated, including hepatocytes, lung epithelial cells, intestinal epithelial cells, and endothelial cells. This system is currently being used in the FAL. 7 . Cells/Organs/Humans-on-a-Chip: In addition to being relevant and reliable, in vitro test systems must be manageable and affordable, with an acceptable rate of throughput, especially if they are to take full account of human variation and contribute toward treating each patient as an individual case, rather than as a member of a homogenous population. Humanisation must be accompanied by miniaturisation, which means taking advantage of progress in microfluidic systems (lab-on-a-chip [LOC] or μ-TAS [micro total analysis systems]), 11, 15 in the development of micro-electro-mechanical-systems (MEMS), leading to the manipulation of nanolitre to femtolitre amounts of fluids. Micro-organoids are encouraged to develop in micro-niches, with micromatrix equivalents and micro-vasculature, combined with micro-sensors. The costs of development will be high, but, given the imperative need for better methods for evaluating efficacy and safety in drug development, coupled with the complexity of diseases themselves and of patient populations, the rewards for success will also be high. It would, perhaps, be wise to focus on mediumthroughput, rather than high-throughput ambitions, since it could be said that the somewhat mindless screening of enormous numbers of compounds for highly-specific properties or narrow interactions has not been very fruitful. That is the main thrust of a chapter by Yuan Wen et al., 15 which is focused on the contributions of microfabrication and chip-based technology to mediumthroughput and high-throughput screen ing. The on-chip detection methods involve optical methods and electrochemical methods, combined with microplate technology. The advantages offered are short processing time, small space requirement, low cost and portability.
The eventual goal is the human-on-a-chip, but which humans will be on the chips? Ideally, there should be a lot of chips, to take full account of the variations within and between human populations, which can profoundly affect the fates of new drugs, as well as the wellbeing of the patients for whom they are prescribed.
As mentioned above, DILI is a key area of focus, not only for the FDA and the IMI, but also for a number of academic and research institutions and international collaborations, including the EU Vitrocellomics project and research at the Hamner-UNC Institute for Drug Safety Sciences, Research Triangle Park, NC, USA, 16 and at the MRC Centre for Drug Safety Sciences, University of Liverpool, UK. 17 Another important collaboration is the International Drug-induced Liver Injury Consortium (iDILIC), which is studying the genetic susceptibility to idiosyncratic drug-induced liver injury, with a UK arm of the study, DILIGEN, funded by the Department of Health. One initiative involves collecting DNA from DILI cases and suitable controls for a Genome Wide Association Study (GWAS), with the aim of identifying polymorphisms predictive of the development of drug-related liver injury, which will open up the possibility of prevention by identifying patients at high risk of developing DILI, by means of a simple test performed before treatment with a particular drug begins. 18, 19 One encouraging aspect of this initiative is that the data obtained are being made publicly available through the Genevar database, so that they can be used by other academic and industrial institutions. 20 It would be particularly useful, if these kinds of initiative could be linked to in vitro studies, so that the predictions from in silico models and omics analyses could be checked experimentally, backed by the identification of biomarkers and resulting in a greater understanding of the mechanisms leading to DILI. It would, for example, be especially useful if hepatocytes could be routinely produced from iPSCs, since the iPSCs could be derived from human subpopulations with a greater susceptibility or greater resistance to DILI, or from patients who had already suffered adverse hepatotoxic effects.
In the light of the application of the multivarious, rapidly-developing, more human-focused, new technologies, and recognition of the importance of two-way translation between the laboratory and the clinic, there is every prospect that the invention and application of medicines will be re-invigorated and that many of the problems associated with DILI and other drug side-effects will be solved, with consequent benefits to the industry and, more importantly, to the patients. Make no mistake, the days of the animal-models-tell-us-all and one-drug-suits-all philosophies are over. 
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